Second Quarter 2025 Results Key Financial Results Revenue: US$264.6m (up ...

Acadia Pharmaceuticals Inc. ACAD) on Wednesday reported second-quarter net income of $26.7 million. The San Diego-based ...

Detailed price information for Amn Healthcare Services Inc (AMN-N) from The Globe and Mail including charting and trades.

ACADIA’s $1B+ 2025 revenue outlook is driven by NUPLAZID and DAYBUE, with ACP-101 offering optional upside despite risks. Read why ACAD stock is a buy.

Acadia Pharma (ACAD) is scheduled to announce Q2 earnings results on Wednesday, August 6th, after market close.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott will lead Acadia’s digital ...

Despite firming US sales of its Rett syndrome treatment Daybue, Neuren Pharmaceuticals (ASX:NEU) says two-thirds of eligible ...

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.

A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggests big pharma may finally be willing to place ...

ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price objective hoisted by JPMorgan Chase & Co. from $30.00 to $34.00 in a report released on Thursday morning,Benzinga reports. The ...

Living within 3 miles of a golf course or using a vulnerable tap water source is associated with an increased risk for Parkinson Disease.

Acadia Pharmaceuticals ACAD reported second-quarter 2025 earnings of 16 cents per share, which beat the Zacks Consensus Estimate of 14 cents. In the year-ago quarter, the company had reported earnings ...